Skip to content

Author

Xiaojun Xu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Nov 2026

Metabolic Reprogramming in Hepatocellular Carcinoma: Liver-Specific Immune Dysfunction, Immunotherapy Resistance, and Translational Biomarker Development.

Hepatocellular carcinoma (HCC) arises in chronically injured, often fibrotic or cirrhotic liver, where metabolism, immunity, vascular and stromal organization, disease etiology, tumor state, and hepatic reserve are tightly interconnected. Although immune checkpoint inhibitor (ICI)-based therapies have expanded treatmen...

Chun-Yan Dai, Shengying Lou, Hua-Li Luo et al. · 0 citations
Aug 2026

HSF1-UCHL1 transcriptional axis protects against MASLD via regulation of PPARα protein stability.

BACKGROUND & AIMS Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most prevalent chronic liver diseases in modern society. Heat shock factor 1 (HSF1) is a transcription factor that orchestrates cellular responses and closely associate with metabolic diseases. However, the specific hepatic...

Yuxiang Cao, Xiangcheng Fan, Meiyao Meng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.